1492 Capital Management LLC Buys New Shares in SOPHiA GENETICS SA $SOPH

Posted by Francis Steltz on Jun 4th, 2026

1492 Capital Management LLC bought a new stake in SOPHiA GENETICS SA (NASDAQ:SOPH – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm bought 208,345 shares of the company’s stock, valued at approximately $973,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Savvy Advisors Inc. purchased a new stake in SOPHiA GENETICS during the 3rd quarter worth about $48,000. Squarepoint Ops LLC purchased a new stake in SOPHiA GENETICS during the 3rd quarter worth about $49,000. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS during the 4th quarter worth about $49,000. GSA Capital Partners LLP purchased a new stake in SOPHiA GENETICS during the 3rd quarter worth about $59,000. Finally, Susquehanna International Group LLP purchased a new stake in SOPHiA GENETICS during the 3rd quarter worth about $88,000. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS Stock Performance

Shares of SOPH stock opened at $4.78 on Thursday. The stock has a market capitalization of $327.38 million, a PE ratio of -9.19 and a beta of 0.98. SOPHiA GENETICS SA has a 52-week low of $2.59 and a 52-week high of $5.70. The stock’s 50-day moving average price is $4.94 and its 200 day moving average price is $4.85. The company has a quick ratio of 1.90, a current ratio of 2.06 and a debt-to-equity ratio of 1.05.

SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $21.69 million during the quarter, compared to analyst estimates of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Insider Transactions at SOPHiA GENETICS

In related news, CEO Jurgi Camblong sold 43,129 shares of the business’s stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $4.96, for a total value of $213,919.84. Following the transaction, the chief executive officer owned 3,664,440 shares in the company, valued at $18,175,622.40. The trade was a 1.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 198,859 shares of company stock valued at $968,527. Insiders own 4.88% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. BTIG Research reiterated a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research report on Wednesday, May 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Tuesday, April 21st. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $7.50.

Check Out Our Latest Stock Report on SOPHiA GENETICS

SOPHiA GENETICS Company Profile

(Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.